9 documents found, page 1 of 1

Prostate cancer progression

AIMS/BACKGROUND: Prostate cancer is the most common malignancy in men and a leading cause of cancer-related death. Progression from non-metastatic castration-resistant prostate cancer (nmCRPC) to metastatic CRPC (mCRPC) significantly worsens health-related quality of life (HRQoL), increases mortality, and raises healthcare costs. This study assessed the impact of avoiding or delaying progression to mCRPC on HRQ...

Processo especial para acordo de pagamento

IN, Repositório do ISCTE-IUL; Este artigo detalha as principais conclusões da análise de 313 processos especiais encerrados de acordo de pagamento realizados no âmbito do projeto de pesquisa IN_SOLVENS. Nosso objetivo é determinar a natureza da intervenção judicial ao longo do processo, a duração média de vários momentos (como as negociações entre o devedor e os credores) e os resultados mais prováveis ​​do pro...

Treatment-Resistant Depression in Portugal

Funding Information: SS is an employee of Janssen-Cilag Farmacêutica Lda. MF is an employee of CTI Clinical Trial and Consulting Services. The remaining authors received advisory board fees from Janssen-Cilag Farmacêutica Lda. AO-M was the national coordinator for Portugal of a non-interventional study EDMS-ERI-143085581, 4.0 to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Jansse...

The LAC Guide

In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-R...

Funding Information: Financed by Fundação para a Ciência e a Tecnologia, I.P./MCTES through national funds (PIDDAC, PT2020) under projects PTDC/MED-QUI/29036/2017, PTDC/BIA-MIC-30692/2017, EXPL/BIA-BFS/1034/2021, UIDB/00100/2020, UIDP/00100/2020, LA/P/0056/2020, UID/Multi/04413/2020, CEECIND/03247/2018 and DL57/CEECIND/0256/2017. Publisher Copyright: Copyright © 2022 Marquês, Frazão De Faria, Reis, Machado, San...

Designing new antitubercular isoniazid derivatives with improved reactivity and...

Funding Information: We acknowledge Diogo Vila Vi?osa for valuable discussions. We acknowledge financial support from Funda??o para a Ci?ncia e a Tecnologia, Portugal through projects PTDC/MED-QUI/29036/2017, PTDC/BIA-MIC-30692/2017, UIDB/00100/2020, UIDP/00100/2020, UIDB/04046/2020, UIDP/04046/2020, and UID/Multi/04413/2020, and Grants CEECIND/02300/2017 and DL57/CEECIND/0256/2017. Contributions from JRK, CMB,...

IN_SOLVENS

Conferência; O projecto IN_SOLVENS partiu da constatação de dois aspectos: a duração média dos processos de insolvência em Portugal excede o que se verifica nos principais centros financeiros mundiais e mesmo a média europeia; a utilização dos mecanismos de pré-insolvência (introduzidos em 2012 e reforçados ao longo dos últimos anos) é ainda residual. O projecto tem um duplo propósito: numa dimen...

A novel BCR-ABL1 mutation in a patient with philadelphia chromosome-positive B-...

cofinanced by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). Inn-INDIGO/0002/2015.; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) represents the most common genetic subtype of adult ALL (20%–30%) and accounts for approximately 50% of all cases in the elderly. It has been considered the subgroup of ALL with the worst outcome. The introduction of tyrosine ki...

Risk-sharing agreements, present and future

Risk-sharing agreements between pharmaceutical companies and payers stand out as a recent practice, the use of which has been increasing in the case of innovative medicines, particularly in the field of oncology, which aims to ensure better budgetary control and a lower risk of spending on medicinal products without full evidence of clinical benefit. In this article, the authors discuss the types of existing ag...